Request Demo
Last update 24 Nov 2025
Mepolizumab biosimilar (Chia Tai-Tianqing)
Last update 24 Nov 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Mepolizumab Biosimilar (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.), 美泊利单抗生物类似药（正大天晴）, 美泊利珠单抗生物类似药（正大天晴药业集团股份有限公司） + [1] |
Target |
Action inhibitors |
Mechanism IL-5 inhibitors(Interleukin-5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 42934L
The sequence is quoted from: *****
Sequence Code 43483H
The sequence is quoted from: *****
Related
1
Clinical Trials associated with Mepolizumab biosimilar (Chia Tai-Tianqing)CTR20244024
单中心、随机、双盲、单剂量、平行比较TQC3566注射液（美泊利单抗注射液）与NUCALA®在中国健康男性志愿者中药代动力学和安全性相似性的I 期临床研究
[Translation] A single-center, randomized, double-blind, single-dose, parallel phase I clinical study comparing the pharmacokinetics and safety of TQC3566 injection (mepolizumab injection) and NUCALA® in healthy Chinese male volunteers
100 Clinical Results associated with Mepolizumab biosimilar (Chia Tai-Tianqing)
Login to view more data
100 Translational Medicine associated with Mepolizumab biosimilar (Chia Tai-Tianqing)
Login to view more data
100 Patents (Medical) associated with Mepolizumab biosimilar (Chia Tai-Tianqing)
Login to view more data
100 Deals associated with Mepolizumab biosimilar (Chia Tai-Tianqing)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Asthma | Phase 1 | China | 04 Nov 2024 | |
| Chronic rhinosinusitis with nasal polyps | Phase 1 | China | 04 Nov 2024 | |
| Churg-Strauss Syndrome | Phase 1 | China | 04 Nov 2024 | |
| Hypereosinophilic Syndrome | Phase 1 | China | 04 Nov 2024 | |
| Granulomatosis With Polyangiitis | IND Approval | China | 22 Dec 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free